Volume 9, Pages (November 2018)

Slides:



Advertisements
Similar presentations
K. Brennan, J.L. Koenig, A.J. Gentles, J.B. Sunwoo, O. Gevaert
Advertisements

Volume 67, Issue 1, Pages (January 2015)
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
Volume 15, Pages (February 2017)
Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non–Small Cell Lung Cancer Patients 
High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer  Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,
Volume 18, Issue 8, Pages (August 2017)
Volume 67, Issue 1, Pages (January 2015)
Kenneth G. Geles, Wenyan Zhong, Siobhan K
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer  Gen Wang, Xiaosong.
Volume 154, Issue 4, Pages e6 (March 2018)
Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer  Peng Kuang, Zuhua.
Spatiotemporal Evolution of the Primary Glioblastoma Genome
A Mitochondrial Power Play in Lymphoma
Volume 18, Issue 8, Pages (August 2017)
Volume 46, Issue 2, Pages (February 2017)
Volume 28, Issue 5, Pages (November 2015)
Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN-γ Enhances Anticancer Responses of Cell Products for Infusion  Marco Donia, Morten Hansen,
Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions  Alessandra Nardin, Wing-Cheong Wong, Charlene Tow,
Volume 27, Issue 3, Pages (March 2015)
Learning More from Microarrays: Insights from Modules and Networks
Somatic promoters correlate with immunoediting signatures.
Volume 17, Issue 1, Pages (January 2010)
Volume 165, Issue 1, Pages (March 2016)
Volume 29, Issue 5, Pages (May 2016)
Volume 15, Issue 9, Pages (May 2016)
Volume 28, Issue 5, Pages (November 2015)
Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer  Meng Zhou, Long Hu, Zicheng.
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept.
Volume 20, Issue 5, Pages (November 2011)
Volume 25, Issue 3, Pages (March 2017)
Volume 4, Issue 3, Pages (August 2013)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Molecular Therapy - Nucleic Acids
Volume 22, Issue 3, Pages (January 2018)
Volume 24, Issue 4, Pages (July 2018)
Ashley M. Laughney, Sergi Elizalde, Giulio Genovese, Samuel F. Bakhoum 
Volume 23, Issue 2, Pages (April 2018)
Volume 17, Issue 8, Pages (November 2016)
Laura S. Bisogno, Matthew B. Friedersdorf, Jack D. Keene
Volume 22, Issue 3, Pages (January 2018)
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
Volume 9, Pages (November 2018)
Volume 25, Issue 13, Pages e6 (December 2018)
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Figure 1. T-cell lymphoma–free survival of untreated and IR-exposed Mlh1−/− mice. Kaplan–Meier survival ... Figure 1. T-cell lymphoma–free survival of.
Utilizing NGS-Data to Evaluate Anti-PD-1 Treatment
Volume 26, Issue 7, Pages e4 (February 2019)
Cancer Evolution during Immunotherapy
Volume 15, Issue 12, Pages (June 2016)
Volume 18, Issue 6, Pages (December 2010)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Volume 167, Issue 2, Pages e9 (October 2016)
Volume 26, Issue 12, Pages e5 (March 2019)
Volume 40, Issue 2, Pages (February 2014)
Covering the Cover Gastroenterology
Network-Based Coverage of Mutational Profiles Reveals Cancer Genes
Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.
Padmanee Sharma, James P. Allison  Cell 
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Volume 28, Issue 3, Pages e7 (July 2019)
Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery  Chen-Tsung Huang, Chiao-Hui Hsieh, Yun-Hsien Chung, Yen-Jen Oyang, Hsuan-Cheng.
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune.
Volume 28, Issue 4, Pages e6 (July 2019)
Transcriptome profiling of PD-L1 antibody–treated macrophages showed inflammatory phenotype, increased survival and proliferation, and decreased apoptosis.
Characteristic gene expression patterns distinguish LCH cells from other immune cells present in LCH lesions. Characteristic gene expression patterns distinguish.
DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.
A. B. C. D. Above median: Below median:
Presentation transcript:

Volume 9, Pages 258-277 (November 2018) Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer  Donghai Xiong, Yian Wang, Arun K. Singavi, Alexander C. Mackinnon, Ben George, Ming You  iScience  Volume 9, Pages 258-277 (November 2018) DOI: 10.1016/j.isci.2018.10.021 Copyright © 2018 The Authors Terms and Conditions

iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 1 Profiles of Mutated Cancer Genes (Nonsilent Somatic Mutations) in the Pre- and Post-anti-PD-1 Treatment Tumor Samples (A) Mutation pattern of Patient 1. (B) Mutation pattern of Patient 2. Indel: insertions or deletions. See also Figure S1, Tables S1 and S2. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Mutation Signatures of Post-anti-PD-1 Treatment Hyperprogressor Tumors (A–C) (A) Commonly mutated genes in the two hyperprogressor tumors, (B) specific mutated genes in Patient 1's hyperprogressor tumor, and (C) specific mutated genes in Patient 2's hyperprogressor tumor. See also Figure S1, Tables S1 and S3. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 3 Activation of Oncogenic Pathways in HP Tumors after Anti-PD-1 Therapy (A and B) (A) Four oncogenic pathways were activated in the HP tumors. (B) The differentially expressed genes in these oncogenic pathways. Most of the genes were upregulated in the HP tumors after anti-PD-1 therapy. HP, hyperprogressive. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 4 Illustration of Clonal Evolution of the Tumors before and after Anti-PD-1 Immunotherapy of the Two Patients with HPD (A–D) (A) Tumor clonal evolution in Patient 1 and (B) tumor clonal evolution in Patient 2. The gray area denotes the tumor clones unaffected by anti-PD-1 therapy, the green and blue areas denote the tumor clones diminishing and appearing due to anti-PD-1 therapy. The dynamics of these clones represented by changes in the variant allele frequency between the pre- and post-therapy tumors was plotted for (C) Patient 1 and (D) Patient 2. See also Figures S5 and S6. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 5 Immunophenoscores of the Hyperprogressor versus Non-hyperprogressor Tumors of the Two Patients Subject to Anti-PD-1 Immunotherapy HLAs were downregulated in the HPD tumors compared with the pre-therapy tumors (shown in the upper left quadrant termed MHC), whereas checkpoints were upregulated in the HPD tumors (shown in the lower left quadrant termed CP). These changes resulted in the overall reduction of immunophenoscores in the HPD tumors resistant to anti-PD-1 immunotherapy. See also Figure S14. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 6 Changes in the Expression of Critical Immune-Related Genes and the Activity of Immune Cell Populations Contribute to Decreased Immunogenicity in the Post-α-PD-1 HPD Tumors (A) Seven genes involved in antigen processing were downregulated, whereas eight genes encoding immune checkpoints or modulators were upregulated in hyperprogressor tumors. (B) The activity of eight immune cell populations were weakened and three were strengthened, as detected by GSVA method. See also Figure S14. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 7 The ILC3 Population Was Activated in the HPD Tumors after Anti-PD-1 Therapy (A–D) (A) GSEA showed that ILC3 marker genes were significantly enriched in the top upregulated genes in HPD tumors resistant to anti-PD-1 therapy. (B) Most of the differentially expressed ILC3 marker genes in the HPD tumors resistant to anti-PD-1 treatment were upregulated. (C) A higher percentage of ILC3 marker genes were upregulated in the nonresponding melanoma tumors resistant to anti-PD-1 therapy based on the analysis of data from an independent study in humans. (D) Upregulation of ILC3 marker genes comparing anti-PD-1-treatment-resistant mouse tumors with untreated tumors in the KrasG12D mouse model. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 8 Activation of Inflammatory Pathways in the HPD Tumors after Anti-PD-1 Treatment (A) GSVA identified the activation of four founder datasets of inflammation pathways. (B) Differentially expressed genes in the inflammatory signature of RESPONSE_TO_CHEMICAL_STIMULUS; (C) Differentially expressed genes in the inflammatory signature of KEGG_CHEMOKINE_SIGNALING_PATHWAY; (D) Differentially expressed genes in the inflammatory signature of INFLAMMATORY_RESPONSE; (E) Differentially expressed genes in the inflammatory signature of CHEMOKINE_ACTIVITY. In each of the four pro-inflammatory datasets from (B–E), there were much more upregulated than downregulated genes. See also Figure S8. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions

Figure 9 Performance of the 121-Gene Set Classifier in the Validation Dataset and Its Effectiveness in the Prognosis of Worse Survival Outcome in the TCGA Datasets (A–D) (A) Receiver operating characteristic (ROC) curves shown for separating HPD patients from non-HPD patients in the validation dataset (Dataset_2, 21 HPD versus 30 non-HPD patients, AUC = 0.91 [95% CI, 0.87–0.96]); Kaplan-Meier analysis showed that the 121-gene set classifier can separate significantly low- and high-risk groups in all of the 13 major TCGA cancers, of which the top three cancers with greatest hazard ratios (HRs) were shown in (B) ESCA (HR = 100.1, 95% CI, 23.1–433.6); (C) COAD (HR = 17.5, 95% CI, 7.4–40.9), and (D) PAAD datasets (HR = 16.0, 95% CI, 8.8–29.0). See also Figures S9–S12. iScience 2018 9, 258-277DOI: (10.1016/j.isci.2018.10.021) Copyright © 2018 The Authors Terms and Conditions